2022 World Conference on Lung Cancer (ePosters)-EP08.02-015. The Utility of Liquid Biopsies for Management of Stage IV Non-small Cell Lung Cancer (NSCLC) in an Academic Community Medical Center

EP08.02-015. The Utility of Liquid Biopsies for Management of Stage IV Non-small Cell Lung Cancer (NSCLC) in an Academic Community Medical Center

Back to course

Pdf Summary

This study aimed to assess the impact of adding liquid biopsies to tissue molecular testing for stage IV non-squamous non-small cell lung cancer (NSCLC). The researchers conducted a retrospective cohort study of patients diagnosed with stage IV non-squamous NSCLC from 2018 to 2021.<br /><br />The primary quality metrics measured were the time required to obtain a molecular diagnosis and the rate of detection of mutations that determine eligibility for first-line small molecule treatments. The study included 124 patients who underwent molecular tissue testing, with 46 of them also undergoing liquid biopsy testing.<br /><br />The results showed that the combined biopsy set had a higher rate of non-smokers and black patients compared to the standard biopsy group. The median time to diagnosis was shorter in the combined set compared to the standard set.<br /><br />Actionable mutations were identified in 48% of the combined set compared to 23% of the standard set. The incidence of informative mutations was higher in the standard set, reflecting the higher incidence of KRAS mutations.<br /><br />Overall, the study demonstrated that patients who underwent liquid biopsy as part of their initial diagnostic workup had a higher rate of detection of actionable mutations and a more rapid determination of their molecular status. This supports the feasibility and utility of performing liquid biopsies as part of the initial evaluation for stage IV non-squamous NSCLC.<br /><br />In conclusion, adding liquid biopsies to tissue molecular testing can improve the diagnosis and treatment options for patients with stage IV non-squamous NSCLC, leading to more personalized and effective care.

Asset Subtitle

Alisha Paro Maity

Meta Tag

Speaker Alisha Paro Maity

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

liquid biopsies

tissue molecular testing

stage IV non-squamous NSCLC

mutation detection

first-line small molecule treatments

time to diagnosis

actionable mutations

KRAS mutations

initial diagnostic workup

personalized care